Company Encyclopedia
View More
name
Sinocelltech
688520.SH
Sinocelltech Group Limited, a biopharmaceutical company, engages in the research and development and production of recombinant proteins, antibody drugs, and vaccines in China. The company offers Anpingxi, an antibody drug and anti-tumor product; Anjiayin for the treatment of hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and SCTV01C and SCTV01E, which are mutant strain recombinant protein vaccines. Its product pipeline includes SCT630 used for the treatment of autoimmune diseases; SCT510 for treating solid tumors; SCT-I10A, a monoclonal antibody injection, which is in phase 3 trials for the treatment of solid tumors; SCTV01 vaccine for the treatment of corona virus; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000 for the treatment of human papillomavirus, as well as SCTA01, which is in phase 2/3 clinical research trials for treating SARS COV-2. The company was founded in 2002 and is based in Beijing, China.
1.601 T
688520.SHMarket value -Rank by Market Cap -/-

Financial Score

08/11/2025 Update
D
BiotechnologyIndustry
Industry Ranking61/79
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreA
    • ROE327.68%A
    • Profit Margin-15.29%D
    • Gross Margin96.48%A
  • Growth ScoreD
    • Revenue YoY-22.80%E
    • Net Profit YoY-1006.03%E
    • Total Assets YoY19.20%A
    • Net Assets YoY59.09%A
  • Cash ScoreE
    • Cash Flow Margin-653.89%E
    • OCF YoY-22.80%E
  • Operating ScoreC
    • Turnover0.55C
  • Debt ScoreE
    • Gearing Ratio101.46%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Sinocelltech released its semi-annual performance report, with a net loss attributable to the parent company of 33.77 million yuan, turning from profit to loss year-on-year

    According to the Zhitong Finance APP, Sinocelltech disclosed its semi-annual report for 2025, reporting revenue of 972 million yuan, a year-on-year decrease of 25.50%; net profit attributable to the parent company was a loss of 33.77 million yuan, turning from profit to loss year-on-year; net profit excluding non-recurring gains and losses was a loss of 36.11 million yuan, also turning from profit to loss year-on-year; basic earnings per share were -0.10 yuan

    Zhitong·
    SH
    688520
    -1.23%
    Zhitong·
    SH
    688520
    -1.23%

    Guotai Junan Securities: China's innovative drugs are in the early stage of realizing innovative achievements, optimistic about the potential emergence of the next blockbuster product in specific segments

    Guojin Securities released a research report indicating that China's innovative drugs are in the early stage of realizing innovation results, and there is hope for the emergence of blockbuster products in the future. The report focuses on sub-sectors such as TCE, dual/multi-antibodies, and innovative ADCs. The report analyzes global clinical trials and drug evolution, believing that BD transactions will experience an explosion, with market focus on the next billion-dollar upfront opportunity. The global tumor immunotherapy is entering a new era, with innovative drug assets rapidly emerging, and the trend of licensing and introduction will continue

    Zhitong·
    HK
    01177
    -2.43%
    HK
    01530
    -6.37%
    SH
    688520
    -1.23%
    Zhitong·
    HK
    01177
    -2.43%
    HK
    01530
    -6.37%
    SH
    688520
    -1.23%

    Sinocelltech: SCT640C injection has received approval for clinical trials

    Sinocelltech announced that its holding subsidiary, Sinocelltech Engineering Co., Ltd., has received the drug clinical trial approval notice from the National Medical Products Administration for its independently developed product SCT640C injection, allowing the clinical trial for adult rheumatoid arthritis indications to proceed

    Zhitong·
    SH
    688520
    -1.23%
    Zhitong·
    SH
    688520
    -1.23%

    Sinocelltech's subsidiary product SCT640C has received approval for clinical drug trials

    According to the Zhitong Finance APP, Sinocelltech announced that recently, its holding subsidiary, Beijing Sinocelltech Biotechnology Group Co., Ltd. (hereinafter referred to as "the Company"), received the "Drug Clinical Trial Approval Notice" approved and issued by the National Medical Products Administration (hereinafter referred to as "NMPA"), agreeing to conduct clinical trials for the product SCT640C injection developed by the Company for the indication of adult rheumatoid arthritis

    Zhitong·
    SH
    688520
    -1.23%
    Zhitong·
    SH
    688520
    -1.23%

    The three major indices of A-shares in Shanghai and Shenzhen fluctuated upwards in the first half of the day, with bank stocks steadily rising

    Today, the three major indices of A-shares showed a fluctuating upward trend, with the Shanghai Composite Index rising 14 points to 3,475 points, the Shenzhen Component Index rising 5 points to 10,540 points, and the ChiNext Index rising 3 points to 2,168 points. Bank stocks rose steadily, with China Construction Bank and ICBC increasing by 1.3% and 1.4%, respectively. Innovative drug concept stocks performed strongly, with Sinocelltech and Cosunter rising by 12.5% and 16.9%, respectively. Photovoltaic stocks retreated, with Oujing Technology and Xiouqiang Co., Ltd. each falling by 6%

    AASTOCKS·
    SH
    601398
    -0.49%
    HK
    01398
    +0.32%
    SH
    688520
    -1.23%
    AASTOCKS·
    SH
    601398
    -0.49%
    HK
    01398
    +0.32%
    SH
    688520
    -1.23%